
Please try another search
The biotech sector is going through the roof right now with SPDR S&P Biotech (MX:XBI) ETF XBI adding over 9% in a month (as of Sep 11, 2017). Plenty of factors are powering the sector. Among these, breakthrough U.S. Food and Drug Administration (FDA) approvals, success in the immune-oncology field, and mergers and acquisitions are at the forefront.
Biotech stock Vertex Pharmaceuticals (NASDAQ:VRTX) received a new FDA approval for cystic fibrosis drug, Kalydeco. In early September, FDA approved “Novartis AG' breakthrough gene transfer treatment, Kymriah (tisagenlecleucel) suspension for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse,” as per the source.
Investors should note that CAR-T is a fresh immunocellular therapy and many companies are eyeing it. In fact, Gilead Sciences (NASDAQ:GILD) announced the buyout of Kite Pharma (NYSE:K) for $11.9 billion in late August (read: Biotech ETFs Soar on Gilead-Kite Deal). Kite Pharma is expected to receive approval for its CAR-T therapy axicabtagene ciloleucel (axi-cel) shortly. With this acquisition, Gilead will step into the new arena of oncology treatment, known as CAR-T, which targets the body’s own immune system to fight tumors.
Two months ago, Clovis Oncology (NASDAQ:CLVS) shares also skyrocketed following the company’s positive cancer drug data. The company then said that clinical trial data on its ovarian cancer drug treatment indicated that it may substantially help more patients than expected (read: 4 Stocks & ETFs to Buy on Clovis' Positive Drug Data).
If this was not enough, Teva Pharmaceutical (NYSE:TEVA) TEVA shares surged over 19% on Sep 11 as it appointed a former Novo Nordisk (CO:NOVOb) (NVO) as CEO. The new recruitment followed Teva’s last full-time CEO’s seven-month term and resignation amid a bribery scandal.
Compelling Valuation
Biotech stocks were the most hurt among the S&P 500 members last year. This has probably made the space cheap and helped it to be back with a bang. Biotech ETF XBI added about 17.7% in the last three months (as of Sep 11, 2017) while SPDR S&P 500 ETF (NYSE:SPY) (AX:SPY) was up 2.9%. The fund XBI has a relative strength index of 66.95. This means that the fund is yet to enter the overbought territory.
Also, fears over price gouging are ebbing substantially in the Trump administration. In a nutshell, the space is riding on research and development and may log more returns ahead.
ETFs to Tap
Below we highlight a few biotech ETFs that can benefit investors with solid gains (see all Health Care ETFs here).
Direxion Daily S&P Biotech Bull 3X LABU
Ultrapro Nasdaq Biotechnology Proshares UBIO
ProShares Ultra Nasdaq Biotechnology BIB
iShare Nasdaq Biotech ETF IBB
Bioshares Biotech Clinical Trial (HM:BBC)
VanEck Vectors Biotech ETF (LON:BBH)
Bioshares Biotech Products (BS:BBP)
Loncar Cancer Immunotherapy ETF CNCR
ALPS Medical Breakthroughs ETF (SI:SBIO)
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Two weeks ago, the rumor mill ramped up again about the potential restructuring of Intel Corporation (NASDAQ:INTC). The probing balloons centered around Taiwan Semiconductor...
More than a century ago, then-Representative William McKinley pursued an aggressive tariff strategy that sought to protect American industry and reduce reliance on foreign...
Early in 2025, value stocks emerged as a popular choice among investors seeking market-beating returns. However, factor-based investing strategies can be notoriously difficult to...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.